Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction (CHIMeRA)
Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)
Sponsor: Groupe Hospitalier Pitie-Salpetriere
Listed as NCT03492242, this observational or N/A phase trial focuses on Arthritis and Autoimmune Diseases and remains completed. Sponsored by Groupe Hospitalier Pitie-Salpetriere, it has been updated 10 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Oct 2019 — Jan 2021 [monthly]
Completed
-
Dec 2018 — Oct 2019 [monthly]
Completed
▶ Show 5 earlier versions
-
Nov 2018 — Dec 2018 [monthly]
Completed
Status: Recruiting → Completed
-
Oct 2018 — Nov 2018 [monthly]
Recruiting
-
Aug 2018 — Oct 2018 [monthly]
Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
First recorded
Feb 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Groupe Hospitalier Pitie-Salpetriere
- Institut National de la Santé Et de la Recherche Médicale, France
For direct contact, visit the study record on ClinicalTrials.gov .